USP8 and hepatocellular carcinoma: USP8 WT, but not C786A and S716A mutants, enhanced cystine uptake and GSH levels of HCC cells, while decreasing lipid ROS levels and cell sensitivity to RSL3 treatment (Figure 6M–P; Figure S7E–H, Supporting Information).